Roles of vascular endothelial growth factor in the angiopoiesis and its targeted therapy

doi:10.3877/cma.j.issn.2095-5820.2015.03.004

Abstract

Abstract:

Progression of tumor depends on angiogenesis in a malignant tissue. Among the numerous endogenous promoters of angiogenesis, vascular endothelial growth factor(VEGF) plays a leading role. VEGF targeted angiogenesis therapy has the remarkable anticancer strategy. So far, there have been many antiangiogenic agents applied in clinic or in clinic trials, including anti VEGF monoclonal antibodies, VEGF receptor kinase inhibitors and small molecular inhibitors targeting on the downstream signal pathways. This review will interpret the VEGF signal system and the status of its targeted treatment. In addition, the mechanism of tumor resistance to antiangiogenic therapy will bee laborated briefly.

Key words: Vascular endothelial growth factor, Antiangiogenic therapy, Target therapy, Tumor resistance

Lu Wang, Yanli Chang, Qingyun Zhang. Roles of vascular endothelial growth factor in the angiopoiesis and its targeted therapy[J]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2015, 03(03): 146-152.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcsysgldzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-5820.2015.03.004

https://zhlcsysgldzzz.cma-cmc.com.cn/EN/Y2015/V03/I03/146

Figures/Tables 2

References 56

[1]	Kerbel RS. Tumor angiogenesis: past, present and the near future[J].Carcinogenesis, 2000, 21(3):505–515.
[2]	Folkman J. Tumor angiogenesis: therapeutic implications[J]. N Engl J Med, 1971, 285(21):1182–1186.
[3]	Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy[J]. Oncologist, 2004, 9 suppl 1:2–10.
[4]	Robinson CJ, Stringer SE. The splice variants of vascular endothelial growth factor (VEGF) and their receptors[J]. J Cell Sci, 2001, 114(5):853 –865.
[5]	Roy H, Bhardwaj S, Ylä-Herttuala S. Biology of vascular endothelial growth factors[J]. FEBS Lett, 2006, 580(12):2879–2887.
[6]	Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothelial growth factor is a secretedangiogenic mitogen[J]. Science, 1989, 246(4935):1306–1309.
[7]	Pajusola K, Aprelikova O, Korhonen J, et al. FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines[J]. Cancer Res, 1992, 52(20):5738–5743.
[8]	Holmes K, Roberts OL, Thomas AM, et al. Vascular endothelial growth factor receptor-2: structure, function, intracellular signaling and therapeutic inhibition[J]. Cell Signal, 2007, 19(10):2003–2012.
[9]	Chu E. An update on the current and emerging targeted agents in metastatic colorectal cancer[J]. Clin Colorectal Cancer, 2011, 11(1):1–13.
[10]	Krauss G. Biochemistry of signal transduction and regulation[M]. 3rd ed. WILEY-VCH Verlag:Weinheim, 2003.
[11]	Simó R, Sundstrom JM, Antonetti DA. Ocular anti-VEGF therapy for diabetic retinopathy: the role of VEGF in the pathogenesis of diabetic retinopathy[J]. Diabetes Care, 2014, 37(4):893–899.
[12]	Takahashi T, Yamaguchi S, Chida K, et al. A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-Adependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells[J]. EMBO J, 2001, 20(11):2768–2778.
[13]	Lee SL, Rouhi P, Dahl JL, et al. Hypoxia-induced pathological angiogenesis mediates tumor cell dissemination, invasion, and metastasis in a zebrafish tumor model[J]. Proc Natl Acad Sci U S A, 2009, 106(46):19485–19490.
[14]	Liu W, Xu J, Wang M, et al. Tumor-derived vascular endothelial growth factor (VEGF)-a facilitates tumor metastasis through the VEGF-VEGFR1 signaling pathway[J]. Int J Oncol, 2011, 39(5):1213–1220.
[15]	Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis[J]. J Clin Oncol, 2005, 23(5):1011–1027.
[16]	Rosen LS. Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers[J]. Cancer Control, 2002, 9(2 suppl):36–44.
[17]	Schmidt NO, Westphal M, Hagel C, et al. Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis[J]. Int J Cancer, 1999, 84(1):10–18.
[18]	Pegram MD, Reese DM. Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and vascular endothelial growth factor[J]. Semin Oncol, 2002, 29(32 suppl 11):29–37.
[19]	Miao HQ, Hu K, Jimenez X, et al. Potent neutralization of VEGF biological activities with a fully human antibody Fab fragment directed against VEGF receptor 2[J]. Biochem Biophys Res Commun, 2006, 345(1):438–445.
[20]	Liang X, Xu F, Li X, et al. VEGF signal system: the application of antiangiogenesis[J]. Curr Med Chemy, 2014, 21(7):894–910.
[21]	Wang M, Zheng X, Ruan X, et al. Efficacy and safety of first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a meta-analysis[J]. Chin Med J (Engl), 2014, 127(3):538–546.
[22]	罗聪, 应杰儿. 贝伐单抗在结直肠癌靶向治疗中的研究进展[J]. 中国全科医学, 2011, 14(29):3407–3409.
[23]	Du J, Lei B, Qin J, et al. Molecular modeling studies of vascular endothelial growth factor receptor tyrosine kinase inhibitors using QSAR and docking[J]. J Mol Graph Model, 2009, 27(5):642–654.
[24]	Minguet J, Smith KH, Bramlage CP, et al. Targeted therapies for treatment of renal cell carcinoma: recent advances and future perspectives[J]. Cancer Chemother Pharmacol, 2015, [Epub ahead of print].
[25]	Dreyer C, Sablin MP, Bouattour M, et al. Disease control with sunitinib in advanced intrahepatic cholangiocarcinoma resistant to gemcitabine-oxaliplatin chemotherapy[J]. World J Hepatol, 2015, 7(6):910–915.
[26]	Choi KJ, Baik IH, Ye SK, et al. Molecular Targeted Therapy for Hepatocellular Carcinoma: Present Status and Future Directions[J]. Biol Pharm Bull, 2015, 38(7):986–991.
[27]	Johnson PJ, Qin SK, Park JW, et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma:Results from the randomized phase III BRISK-FL study[J]. J Clin Oncol, 2013, 31(28):3517–24.
[28]	Lai L, Liu J, Zhai D, et al. Plumbagin inhibits tumour angiogenesis and tumour growth through the rassignalling pathway following activation of the VEGF receptor-2[J]. Br J Pharmacol, 2012, 165(4b):1084–1096.
[29]	Gibney GT, Gauthier G, Ayas C, et al. Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting[J]. Cancer Med, 2015,[Epub ahead of print].
[30]	Chelouche-Lev D, Miller CP, Tellez C, et al. Different signalling pathways regulate VEGF and IL-8 expression in breast cancer: implications for therapy[J]. Eur J Cancer, 2004, 40(16):2509–2518.
[31]	Dry JR, Pavey S, Pratilas CA, et al. Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244)[J]. Cancer Res, 2010, 70(6):2264–2273.
[32]	American Society of Clinical Oncology (ASCO). 2012 ASCO Annual Meeting: METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progressionfreesurvival (PFS) and overall survival (OS), compared with chemotherapy (C) in patients (pts) with BRAFV600E/K mutant advanced or metastatic melanoma (MM). Accessed 2012]. URL
[33]	Rizos H, Menzies AM, Pupo GM, et al. BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact[J]. Clin Cancer Res, 2014, 20(7):1965–1977.
[34]	Larkin J, Ascierto PA, Dréno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma[J]. N Engl J Med, 2014, 371(20):1867–1876.
[35]	Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma[J]. N Engl J Med, 2014, 371(20):1877–1888.
[36]	Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib[J]. N Engl J Med, 2015, 372(1):30–39.
[37]	Song Y, Dai F, Zhai D, et al. Usnic acid inhibits breast tumor angiogenesis and growth by suppressing VEGFR2-mediated AKT and ERK1/2 signaling pathways[J]. Angiogenesis, 2012, 15(3):421–432.
[38]	Liu LZ, Li C, Chen Q, et al. MiR-21 induced angiogenesis through AKT and ERK activation and HIF-1alpha expression[J]. PLoS One, 2011, 6(4):e19139.
[39]	Li C, Xin P, Xiao H, et al. The dual PI3K/mTOR inhibitor NVP-BEZ235 inhibits proliferation and induces apoptosis of burkitt lymphoma cells[J]. Cancer Cell Int, 2015, 15:65.
[40]	Agarwal E, Chaudhuri A, Leiphrakpam PD, et al. Akt inhibitor MK-2206 promotes anti-tumor activity and cell death by modulation of AIF and Ezrin in colorectal cancer[J]. BMC Cancer, 2014, 14:145.
[41]	Banumathi E, O’Connor A, Gurunathan S, et al. VEGF-induced retinal angiogenic signaling is critically dependent on Ca²⁺ signaling by Ca²⁺/calmodulin-dependent protein kinase II[J]. Invest Ophthalmol Vis Sci, 2011, 52(6):3103–3111.
[42]	Pieramici D, Rabena M. Anti-VEGF therapy: comparison of current and future agents[J]. Eye (Lond), 2008, 22(10):1330–1336.
[43]	Sitohy B, Nagy JA, Dvorak HF. Anti-VEGF/VEGFR therapy for cancer: reassessing the target[J]. Cancer Res, 2012, 72(8):1909–1914.
[44]	BD. Advanced Information: RNA interference. Nobel Media AB: nobelprize.org [website on Internet].Available from: Accessed 8 November 2012]. URL
[45]	Chen S, Feng J, Ma L, et al. RNA interference technology for anti-VEGF treatment[J]. Expert Opin Drug Deliv, 2014, 11(9):1471–1480.
[46]	Chekhonin VP, Shein SA, Korchagina AA, et al. VEGF in tumor progression and targeted therapy[J]. Curr Cancer Drug Targets, 2013, 13(4):423–443.
[47]	Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients[J]. Cancer Cell, 2007, 11(1):83–95.
[48]	Fan F, Samuel S, Gaur P, et al. Chronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumour cell migration[J]. Br J Cancer, 2011, 104(8):1270–1277.
[49]	Du R, Lu KV, Petritsch C, et al. HIF1 alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion[J]. Cancer Cell, 2008, 13(3):206–220.
[50]	Hu YL, DeLay M, Jahangiri A, et al. Hypoxia-induced autophagy promotes tumor cell survival and adaptation to antiangiogenic treatment in glioblastoma[J]. Cancer Res, 2012, 72(7):1773–1783.
[51]	Pàez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis[J]. Cancer Cell, 2009, 15(3):220–231.
[52]	Ebos JM, Lee CR, Cruz-Munoz W, et al. Accelerated metastasis after shortterm treatment with a potent inhibitor of tumor angiogenesis[J]. Cancer Cell, 2009, 15(3):232–239.
[53]	Sakariassen PØ, Prestegarden L, Wang J, et al. Angiogenesis-independent tumor growth mediated by stem-likecancer cells[J]. Proc Natl Acad Sci U S A, 2006, 103(44):16466–16471.
[54]	Kondo Y, Kanzawa T, Sawaya R, et al. The role of autophagy in cancer development and response to therapy[J]. Nat Rev Cancer, 2005, 5(9):726–734.
[55]	Hu YL, Jahangiri A, Delay M, et al. Tumor cell autophagy as an adaptive response mediating resistance to treatments such as antiangiogenictherapy[J]. Cancer Res, 2012, 72(17):4294–4299.
[56]	Wu X, Northcott PA, Dubuc A, et al. Clonal selection drives genetic divergence of metastatic medulloblastoma[J]. Nature, 2012, 482(7386):529–533.

商品名	单克隆抗体	临床应用	药物靶点	研发公司
阿瓦斯汀	贝伐单抗	治疗多种肿瘤，包括结直肠癌、肺癌、乳腺癌、胶质母细胞瘤、肾癌、卵巢癌	VEGF-A	基因技术/罗氏
诺适得	雷珠单抗	治疗年龄相关性黄斑变性	VEGF-A	基因技术
爱必妥	西妥昔单抗	治疗转移性结直肠癌、头颈部肿瘤	EGFR	默克
维克替比	帕尼单抗	治疗转移性结直肠癌	EGFR	安进
	IMC-1C11	结直肠癌患者肝转移的I期临床试验	VEGFR-2
	Ycom 1D3	临床前研究阶段	VEGFR-2（KDR）
	TB-403	早期临床试验	PLGF	丹麦药物署

商品名	单克隆抗体	临床应用	药物靶点	研发公司
阿瓦斯汀	贝伐单抗	治疗多种肿瘤，包括结直肠癌、肺癌、乳腺癌、胶质母细胞瘤、肾癌、卵巢癌	VEGF-A	基因技术/罗氏
诺适得	雷珠单抗	治疗年龄相关性黄斑变性	VEGF-A	基因技术
爱必妥	西妥昔单抗	治疗转移性结直肠癌、头颈部肿瘤	EGFR	默克
维克替比	帕尼单抗	治疗转移性结直肠癌	EGFR	安进
	IMC-1C11	结直肠癌患者肝转移的I期临床试验	VEGFR-2
	Ycom 1D3	临床前研究阶段	VEGFR-2（KDR）
	TB-403	早期临床试验	PLGF	丹麦药物署

Please choose a citation manager

Content to export